Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price target increased by The Goldman Sachs Group from $38.00 to $42.00 in a report published on Thursday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other equities analysts have also recently weighed in on the stock. Wells Fargo […]
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. […]
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have received an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price […]
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CFO Hunter C. Smith sold 7,026 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $35.06, for a total transaction of $246,331.56. Following the sale, the chief financial officer now directly owns 61,406 shares in […]
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 […]